These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 27525726)

  • 1. Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib.
    Droege F; Thangavelu K; Lang S; Geisthoff U
    Ann Hematol; 2016 Dec; 95(12):2077-2078. PubMed ID: 27525726
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120.
    Geisthoff UW; Nguyen HL; Hess D
    Ann Hematol; 2014 Apr; 93(4):703-4. PubMed ID: 23892886
    [No Abstract]   [Full Text] [Related]  

  • 3. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.
    Sun FK; He HC; Su TW; Zhou WL; Huang X; Dai J; Shen ZJ
    Chin Med J (Engl); 2012 Jun; 125(12):2231-4. PubMed ID: 22884159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab and hereditary haemorrhagic telangiectasia.
    Cruikshank RP; Chern BW
    Med J Aust; 2011 Mar; 194(6):324-5. PubMed ID: 21426291
    [No Abstract]   [Full Text] [Related]  

  • 5. The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
    Addeo R; Caraglia M
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):139-42. PubMed ID: 21342029
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
    Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
    Skubitz KM; Manivel JC; Clohisy DR; Frolich JW
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):635-40. PubMed ID: 19404642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 9. Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma.
    Lee CH; Motzer RJ
    Urol Oncol; 2015 Jun; 33(6):275-9. PubMed ID: 25465298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of sunitinib as a therapy in ovarian cancer.
    Leone Roberti Maggiore U; Valenzano Menada M; Venturini PL; Ferrero S
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1671-86. PubMed ID: 24070205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressing effects of sunitinib on allergic rhinitis: previously undefined side effects with therapeutic potential.
    Eechoute K; van Zonneveld M; van Daele PL; van Wijk RG; Mathijssen RH
    J Clin Pharmacol; 2011 Nov; 51(11):1592-5. PubMed ID: 21189307
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
    Currás Freixes M; Díaz Pérez JÁ; Casado Herráez A; Ochagavía Cámara S
    Endocrinol Nutr; 2014 Jan; 61(1):62-3. PubMed ID: 24125629
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.
    Geisthoff UW; Seyfert UT; Kübler M; Bieg B; Plinkert PK; König J
    Thromb Res; 2014 Sep; 134(3):565-71. PubMed ID: 25005464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib malate in the treatment of urothelial cancer.
    Pons F; Bellmunt J
    Expert Opin Investig Drugs; 2014 Jan; 23(1):115-24. PubMed ID: 24188025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.
    Pantaleo MA; Nannini M; Di Battista M; Catena F; Biasco G
    Cancer Treat Rev; 2010 Feb; 36(1):63-8. PubMed ID: 19914780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary hemorrhagic telangiectasia: a review of 76 cases.
    Shah RK; Dhingra JK; Shapshay SM
    Laryngoscope; 2002 May; 112(5):767-73. PubMed ID: 12150604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.